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ABSTRACT
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision 
oncology workflows are typically limited to targeted and/or disease-specific 
applications. In advanced cancer, disease burden and cfDNA tumor content are often 
elevated, yielding unique precision oncology opportunities. We sought to demonstrate 
the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach 
(PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) 
tumor content determination through genome-wide copy number alteration (CNA) 
profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 
100 patients with advanced cancers, including 76 men with metastatic castration-
resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation 
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and actionable focal CNA detection, while facilitating concordance analyses between 
cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations 
with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present 
in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples 
harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles 
facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA 
enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. 
In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed 
high concordance (median Pearson correlation = 0.87), and PRINCe detectable 
AR amplifications predicted reduced time on therapy, independent of therapy type 
(Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach 
enables robust, broadly applicable cfDNA-based precision oncology for patients with 
advanced cancer through scalable identification of therapeutically relevant CNAs and 
pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision 
oncology workflow optimization.
INTRODUCTION
Clinical and commercial next-generation 
sequencing (NGS) based precision oncology strategies 
have expanded rapidly [1, 2]. Both targeted [3–8] and 
more comprehensive [9, 10] NGS assessment of frozen 
and archived formalin-fixed paraffin-embedded (FFPE) 
tissue samples have proven effective in identifying 
certain categories of clinically informative somatic DNA-
based alterations, but tissue and re-biopsy requirements 
serve as considerable hurdles for widespread clinical 
implementation for identifying and tracking clinically 
relevant genomic alterations.
Myriad noninvasive (‘liquid biopsy’) approaches 
for identifying and tracking clinically relevant genomic 
alterations from cell-free DNA (cfDNA) have emerged as 
viable and potentially more broadly applicable alternatives 
to tissue-based assays using technologies including 
quantitative PCR (qPCR), digital droplet PCR (ddPCR), 
targeted DNA sequencing, and whole exome (WES) or 
whole genome sequencing (WGS) [2, 10–31]. Identifying 
a tractable, scalable precision oncology workflow with 
utility across patients with various advanced cancers, 
however, is still a substantial challenge given the 
variability of tumor-derived circulating cfDNA content, 
relevant genomic alterations, and frequent need for ultra-
deep (e.g. > 10,000x), high-sensitivity sequencing in order 
to ensure detection (or absence) of clinically relevant 
alterations in pan-cancer cohorts [25, 32]. 
Genome-wide copy number profiles derived from 
low-pass cfDNA whole genome sequencing (WGS) are 
routinely used to detect large-scale aneuploidy events in 
clinical applications such as screening for fetal anomalies 
during pregnancy [33–36]. Multiple experiments have 
leveraged similar principles using low-pass cfDNA WGS 
to infer somatic whole-genome copy-number profiles in 
patients with advanced cancer, occasionally deploying 
higher depth disease-specific strategies for approximating 
cfDNA tumor content [22, 37–41]. However, these 
approaches often rely on disease specificity trade-offs 
that limit widespread prospective implementation [39]. 
Applicability across cancers, routine identification of 
actionable CNAs, correlation with comprehensive tissue 
based NGS profiling, and use as a precision oncology 
screen strategy have not yet been comprehensively 
addressed [40, 41]. Initiatives comparing comprehensive 
tissue-based molecular profiles to those obtained from 
cfDNA have also thus far been limited in size, particularly 
in metastatic castration resistant prostate cancer (mCRPC) 
[30, 31, 40]. 
Here, as part of an effort to facilitate precision 
medicine for all patients with advanced cancer, we propose 
a comprehensive approach deploying rapid, inexpensive, 
ultra-low pass cfDNA WGS as a broadly applicable 
potential screening strategy through: 1) directly identifying 
actionable CNAs, 2) informing needed sequencing depth 
for additional comprehensive/targeted cfDNA assessment 
(through cfDNA tumor content approximation) and 3) 
reserving ultra-deep cfDNA sequencing or tissue-based 
profiling for patients with low cfDNA tumor content. 
We show that with effective whole-genome coverage as 
low as 0.01× (< 100,000 single end reads) per sample 
on a benchtop Ion Torrent sequencer from as little as 10 
pg of double-stranded DNA, we can recapitulate known 
whole-genome copy number profiles in cell lines and 
advanced prostate, colon, lung, and breast cancer patient 
samples, while retaining the ability to identify both focal 
and broad CNAs with megabase-level resolution. To 
confirm the utility of this screening approach to guide 
additional precision oncology assessment, we also paired 
this ultra-low-pass WGS with targeted multiplexed PCR 
based NGS of the same cfDNA, validating CNAs and 
identifying clinically relevant somatic mutation profiles 
at depth tuned by WGS-informed cfDNA tumor content 
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approximation. Further, we directly compare cfDNA 
copy-number and mutational profiles with molecular 
profiles from synchronous or asynchronous tissue samples, 
highlighting high overall concordance and unique 
considerations for comprehensive precision oncology 
workflows, while exploring associations between putative 
cfDNA biomarkers and therapeutic outcomes in patients 
with mCRPC. 
RESULTS
Rationale for a pan-cancer, rapid, inexpensive, 
ultra-low pass NGS cfDNA (PRINCe) approach 
to guide precision oncology
The major impetus for ultra-deep, high sensitivity 
cfDNA profiling in precision oncology is the need for 
robust sensitivity and specificity for somatic alterations 
detection at extremely low cfDNA tumor content [42]. 
While many cfDNA-based detection approaches thus 
rely heavily on targeted, ultra-sensitive methodologies, 
many patients with elevated tumor burden or metastatic 
treatment refractory cancer—where precision oncology 
NGS is most commonly employed—have relatively high 
cfDNA tumor contents of 5–50% [22, 25, 42] (Figure 1A). 
If tumor-derived cfDNA characteristics could be rapidly 
leveraged to approximate tumor content and potentially 
identify clinically relevant alterations across cancer types, 
unique and potentially more optimized precision medicine 
strategies may be achievable. Given that somatic copy-
number alterations (CNAs) are pervasive in cancer [43] 
and somatic copy-number burden may be an important 
marker for aggressive or treatment-resistant disease 
[44], we first assessed the prevalence of extended copy-
number burden in a pan-cancer TCGA cohort using 11,576 
copy number profiles from 32 tumor types (Figure 1B). 
Overall, 56% of tumors had elevated copy-number burden 
(defined by having > 15% fraction of the genome altered 
[FGA]), with FGA increasing with pathologic tumor stage, 
tumor grade and clinical stage (Supplementary Figure 1). 
Importantly, per-sample FGA was also increased in a 
cohort of advanced/metastatic tumors (n = 129) profiled 
as part of the MI-ONCOSEQ project [45] compared to 
the TCGA cohort, with 81% of Mi-ONCOSEQ profiled 
tumors having > 15% FGA (Figure 1B). As CNAs can 
be robustly detected at substantially lower sequencing 
coverage (and cost) than typically required for somatic 
mutation calling in genome-wide or targeted pan-cancer 
workflows, we sought to exploit genome-wide CNAs as 
a biomarker through a pan-cancer, rapid, inexpensive, 
ultra-low pass NGS cfDNA (PRINCe) precision oncology 
screening approach, which has the potential to directly 
inform precision oncology workflows through genome-
wide CNA detection and tumor content approximation 
(Figure 1C). 
Validation of ThruPLEX cfDNA WGS for Ion 
torrent benchtop sequencers and cfDNA tumor 
content approximation
Validation of cfDNA WGS using a three hour 
ThruPLEX RGP-0003 WGA single tube library construction 
approach (compatible with ≤ 50pg double stranded DNA) 
for rapid sequencing on Ion Torrent benchtop sequencers 
was carried out on 10 normal control cfDNA samples, all 
of which displayed high sequencing coverage uniformity (> 
90%) (Supplementary Table 1 and Supplementary Results). 
In vitro dilution experiments of sheared genomic DNA for 
VCaP (prostate cancer) and UMUC-5 (bladder cancer) cell 
lines confirmed our ability to leverage Ion Torrent cfDNA 
WGS for recapitulation of whole-genome copy number 
profiles and detection of therapeutically relevant focal 
amplifications (including AR and EGFR amplifications), 
with high observed concordance with orthogonal targeted 
and genome-wide copy-number profiles at tumor contents 
as low as 5% (see Supplementary Figures 2 and 3, Methods, 
Supplementary Results) [46, 47]. 
Subsequent in silico dilution and downsampling 
experiments of cell line (sheared gDNA) and patient 
cfDNA WGS data facilitated development of a 
heuristic tumor content approximation metric (least 
squares statistic; LSS), while highlighting our ability to 
recapitulate both broad and focal copy-number alterations 
across tumor contents as low as 5% (see Supplementary 
Figures 3–5, Supplementary Methods). While detection 
of focal amplifications by low-pass cfDNA WGS is also 
dependent on absolute copy-number of amplified gene(s) 
in the tumor, high-level focal amplifications (>4 copies) 
are frequent across TCGA and advanced cancers [48, 
49], and abundant and detectable in our patient cohort 
(described below). An illustrative example of a genome-
wide copy-number profile from cfDNA collected from 
a patient (TP1337) with mCRPC after progression 
on second generation anti-androgens abiraterone and 
enzalutamide is shown in Figure 2A. TP1337 harbored 
focal AR amplification, chr8q gain, focal 2-copy 
PTEN loss, and one-copy loss on chr13 including RB1, 
representing the majority of the most common CNAs 
in mCRPC [45]. Figure 2B further displays the ability 
of our approach to detect both broad and focal CNAs 
down to 0.005x (~82,000 reads) in TP1337, with routine 
robust detection of focal amplifications in cell lines and 
high tumor content mCRPC samples at 0.01x coverage 
(Supplementary Figures 6 and 7). While ultra-low-pass 
(0.005×) is expected to have greatest clinical utility in 
high-tumor content cfDNA samples, these results support 
the fidelity of copy number profiling from cfDNA using 
our low-pass WGS based PRINCe approach and the 
capacity to leverage this workflow to both approximate 
tumor content and identify high level focal amplifications, 
a key therapeutic class of somatic alterations in cancer. 
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Application of PRINCe to patient cfDNA sample 
cohorts and utility in disease monitoring
To demonstrate feasibility and utility of PRINCe in 
representative clinical scenarios, we next assessed cfDNA 
from two patient cohorts, one comprised of 31 samples 
from 24 individual patients with metastatic colorectal, 
breast, or lung cancers, uterine leiomyosarcoma, sarcoma, 
or leukemia, and another comprised of 93 samples from 
75 patients with mCRPC (including patients with both 
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low and high volume disease) (Supplementary Table 1). 
Across the 124 total patient samples, 74 (59%) had 
LSS values ≥ 0.1, and thus an estimated cfDNA tumor 
content of > 8.75% (Figure 2C, Supplementary Results). 
PRINCe enabled routine detection of actionable focal 
copy-number alterations (including focal EGFR and 
FGFR1 amplifications) across patient samples in our non-
mCRPC cohort (Figure 2D); combining this approach 
with targeted cfDNA enabled robust detection of ddPCR 
validated informative point mutations or indels (including 
EGFR exon 19 deletions) (see Supplementary Results). 
PRINCe profiling of serial cfDNA samples from several 
patients highlighted utility in evaluating treatment 
response, disease monitoring, and identification of 
candidate biomarkers of treatment response in a patient 
(PD-L1006_1) with stage IV lung adenocarcinoma who 
achieved a complete response to PD-L1 checkpoint 
inhibition immunotherapy (see Supplementary Results). 
While there remains clear utility in specific contexts 
for profiling disease recurrence at extremely low tumor 
content using high-depth, ultra-sensitive or personalized 
sequencing/ddPCR methodologies [32, 50, 51], our 
results suggest substantial potential clinical utility across 
cancer types from low-cost identification of pre-treatment 
genome wide CNA profiles and cfDNA tumor content 
estimates via highly scalable whole-genome and targeted 
cfDNA NGS-based profiling strategies to monitor disease 
burden and molecular evidence of response.
PRINCe applied to metastatic castration 
resistant prostate cancer (mCRPC)
Given the potential impact of CNA detection in 
cfDNA—particularly AR amplification—on therapeutic 
decision-making in prostate cancer [23, 52, 53], we next 
focused on the 76 patients with mCRPC. All patients had 
progressive disease after androgen deprivation therapy, 
and the clinical characteristics are shown in Supplementary 
Tables 2 and 3. PRINCe was carried out on 5 normal male 
and 93 mCPRC patient samples (including one technical 
replicate, TP1052B) to average whole-genome coverage 
of 0.32x (range: 0.02–1.30x)). Of 93 mCRPC cfDNA 
samples, 60 (65%) had estimated tumor contents greater 
than 8.75% by LSS analysis (LSS ≥ 0.1), our minimum 
threshold for accurately estimating tumor content, and 
were considered as high tumor content. Low-pass WGS 
of one cfDNA sample (TP1330) identified a single 19Mb 
deletion on chr20 (20q11.21–20q13.2) leading to elevated 
LSS, while by targeted NGS this sample also carried 
a U2AF1 S34F COSMIC hotspot mutation (variant 
fraction = 30%, 527 covering reads; Supplementary 
Table 4), consistent with contaminating white blood cell 
cfDNA in the presence of concurrent myelodysplastic 
syndrome [54], and thus this sample was considered as 
low tumor content for subsequent analyses (Figure 2B 
and Supplementary Figure 8; see Methods). In total, the 
63% (59 of 93) of mCRPC samples with estimated tumor 
content >8.75% represent a similar proportion of mCRPC 
samples to that reported as having sufficient tumor derived 
cfDNA for array CGH and targeted NGS based assessment 
described by Wyatt et al. [55]. 
Unsurprisingly, 68 of 93 mCRPC cfDNA samples 
(73%) showed evidence of detectable chromosome 8p 
losses and/or 8q gain (known early alterations in prostate 
carcinoma progression [56, 57]), including 58 of 59 (98%) 
high tumor content samples (Supplementary Figure 9). 
In total, 14 of 93 (15%) mCRPC cfDNA samples also 
demonstrated detectable segmented 21q22.2 copy-
number deletions consistent with deletion leading to 
TMPRSS2:ERG gene fusion, another known early event 
in prostate oncogenesis [58, 59] (Supplementary Figure 
10). Focal copy number alterations were also frequent, 
including PTEN deletion (20 of 59 (28.8%) high tumor 
content cfDNA samples, 11 (65%) of which are focal 
deep deletions (Supplementary Figure 10)), and focal AR 
amplification (36 of 93 (39%) cfDNA samples, including 
32 of 59 (54%) high tumor content mCRPC samples) 
(Supplementary Figure 10, Supplementary Table 1), 
Figure 1: Leveraging tumor-derived cfDNA distribution in advanced cancer to develop a pan-cancer, rapid, inexpensive, 
ultra-low pass whole genome next generation sequencing (NGS) cfDNA precision oncology workflow (PRINCe). (A) 
Theoretical cfDNA tumor content distributions and typical next-generation sequencing (NGS) coverage requirements for mutation profiling 
are presented for early detection (left) and precision oncology in advanced disease (right) applications. In early detection context, the 
majority of cfDNA samples are expected to have a low proportion of tumor-derived cfDNA fragments (e.g., < 5%), whereas advanced 
cancers have an elevated proportion of tumor-derived cfDNA. Tumor content requiring ultra-deep, extreme-fidelity (e.g. 10,000x coverage) 
targeted sequencing are shaded red, while those amenable to targeted sequencing on larger panels or whole-exome/whole-genome (WES/
WGS) are shaded blue and green, respectively. (B) Copy number alterations (CNAs) are frequent across human cancers. The fraction of 
the genome altered (FGA, see Methods) by CNAs in 11,576 The Cancer Genome Atlas (TCGA) samples from 32 solid tumor types is 
shown across multiple thresholds (overall cohort on left, individual tumor types on right). Increased FGA in a cohort of 129 advanced/
metastatic cancers (prostate, kidney, lung and breast cancers) subjected to exome sequencing in the MI-ONCOSEQ program (plotted on 
the right panel) is seen in comparison to the TCGA cohort, consistent with increasing frequency of CNAs in advanced/metastatic cancers. 
(C) Schematic for pan-cancer, rapid, inexpensive, ultra-low pass NGS cfDNA workflow (PRINCe). Segmented copy-number calls from 
ultra-low-pass cfDNA whole-genome sequencing are generated, followed by CNA-clustering based tumor content approximation to inform 
on precision oncology management. In patients with sufficient tumor content by PRINCe (e.g. > 5–10%), CNA profiles may directly guide 
treatment (if focal targSupplementary Table alterations are identified), enable routine panel, WGS, or WES based cfDNA NGS tuned 
to tumor content, as well as establish pre-treatment (tx) CNA profiles for disease (dx) monitoring post-therapy. More costly ultra-deep, 
extreme fidelity cfDNA and tissue based profiling can thus be reserved for patients with low cfDNA tumor content. 
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both of which are biomarkers of poor prognosis and/or 
resistance to second-line anti-androgens (abiraterone and 
enzalutamide), particularly when observed in cfDNA 
[23, 52, 53, 60] (see Supplementary Results). Focal RB1 
deletion, a frequent alteration in neuroendocrine/small-cell 
prostatic carcinoma [45, 61], was also detectable by our 
approach, with 4 samples (4.3%) (4 patients) exhibiting 
focal deep deletions (Supplementary Figure 10), 
including 1 from a patient (TP1320) with detectable AR 
amplification, who (post-ADT and a single course of 
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docetaxel) progressed rapidly on abiraterone over the 
course of 3 months on therapy with PCa-related death 4 
months after cfDNA profiling (Supplementary Table 2; see 
Supplementary Results). 
Notably, PRINCe assessment of cfDNA sample 
TP1291 paired with targeted NGS of the matched 
unamplified cfDNA (described below) identified a broad 
1-copy copy-number loss affecting BRCA2 and RB1 in 
combination with a Clinvar pathogenic BRCA2 germline 
R2494X stop-gain SNV at a variant fraction (71%, 1,022 
variant-containing reads) consistent with copy-number 
deletion of the non-mutated copy of the gene and biallelic 
inactivation of BRCA2 (Supplementary Figure 11). Prior 
to cfDNA sample collection, the corresponding patient 
progressed rapidly through courses of abiraterone, 
enzalutamide, docetaxel, and cabazitaxel over the 11 
months prior to cfDNA sample collection, consistent 
with known poor prognosis for BRCA-mutant men with 
prostate cancer [62], confirming important utility for 
cfDNA profiling in guiding PARP inhibitor treatment in 
patients with advanced prostate cancer [30, 31]. Additional 
PRINCe assessments detected a putative complex 
rearrangement affecting BRCA1 in a patient with mCRPC, 
along with clinically relevant copy-number alterations 
in advanced treatment-naïve patients with heavy tumor 
burden (Supplementary Figure 11; see Supplementary 
Results). Overall, these results highlight our capacity 
to detect therapeutically relevant focal copy-number 
deletions from low-pass cfDNA WGS in patients with 
mCRPC and support potential clinical utility in informing 
precision oncology workflows for patients with advanced 
prostate cancer.
PRINCe to guide additional precision oncology 
testing
In the absence of immediately actionable copy-
number alterations by low-pass WGS, a priori tumor 
content approximation from low-pass cfDNA WGS can 
enhance subsequent precision medicine workflows by 
directly informing requisite strategies or coverages needed 
for meaningful NGS profiling (Figure 1C). For example, 
we hypothesized that in patients with relatively high 
cfDNA tumor content (e.g. >10%), routine tumor tissue 
profiling NGS strategies would be sufficient to detect 
relevant alterations, rather than ultra-high depth, high 
fidelity (e.g. single molecule barcoding) sequencing as 
typically performed for cfDNA NGS. Hence, we subjected 
separate 1–20 ng aliquots of unamplified cfDNA from 61 
of our patient samples (including 46 mCRPC samples, 
11 high tumor content non-mCRPC samples, and 4 male 
control samples with sufficient DNA; see Supplementary 
Table 1), as well as the undiluted artificial VCaP and 
UMUC5 cfDNA samples as positive controls, to targeted 
multiplexed PCR based NGS using the DNA component 
of the Oncomine Cancer Assay (OCP) [4], the panel being 
used in the NCI sponsored MATCH trial performing NGS 
on tumor tissue. 
Sequencing of pooled patient samples resulted in a 
median average coverage of 1,075x (range: 42–17,944×), 
with average uniformity of 96.0% (higher than typically 
observed for FFPE DNA samples [4]). OCP on cfDNA 
confirmed high level EGFR amplification in UMUC-
5, and high level AR amplifications in VCaP and 23 of 
23 (100%) high tumor content mCRPC samples. In 
Figure 2: cfDNA tumor content approximation and disease monitoring applications for targeted and ultra-low-
pass whole-genome sequencing (WGS) of cell-free DNA from patients with advanced cancer. (A) Genome-wide 
log2(CopyNumberRatio) (Log2CN) calls for TP1337, a high tumor content cfDNA sample from a patient with mCRPC, are displayed for 
low-pass WGS data (0.82x whole-genome coverage) and targeted NGS data. Key copy-number alterations (CNA) detected are circled, 
including broad gain of 8q (green), focal amplification of chr11p11.2 (purple) and AR (orange), and focal RB1 (1-copy; pink) and PTEN (2-
copy; red) deletions. Copy number and mutation data from deep coverage targeted NGS data is provided at right from unamplified TP1337 
cfDNA (1,102× targeted NGS coverage) using the DNA component of the Oncomine Comprehensive Assay (OCP), a pan cancer NGS 
panel developed for FFPE tissue samples. For genes with sufficient amplicons for CNA calling, amplicon (dots) and gene (black bars)-level 
log base 2 copy number ratio (Log2 [CN Ratio]) estimates (compared to a composite reference sample) are plotted. All CNAs seen by low-
pass WGS are detected via targeted NGS CNA analysis (chr11p11.2 is not targeted by OCP). A prioritized high confidence somatic 28 bp 
frameshift deletion in TP53 (p.L264del28bp; variant fraction (VF) = 20.8% (105/504 total sequencing reads)) detected by OCP is shown 
in the inset box. (B) In silico downsampling experiments highlight the ability to detect both focal and broad copy-number alterations from 
TP1337 cfDNA WGS data at whole-genome coverages down to 0.005×. Bin size and number of high-quality (MAPQ ≥ 37) mapped reads 
used for copy-number analysis are indicated at each coverage, and regions affected by copy-number alterations detected in original low-
pass WGS are circled. (C) Distribution of cfDNA tumor content estimates (right axis) from least-squares distance metric (LSS) values (left 
axis) for 124 patient cfDNA samples (123 from patients with advanced cancer, including TP1178 (from a patient with untreated advanced 
prostate cancer), along with 1 normal control sample (TP1147). All patient samples are colored by cancer type (indicated in the legend). (D) 
Low-pass WGS copy-number for pre- and post- EGFR inhibitor (erlotonib) treatment plasma cfDNA samples from ULMC-125, a patient 
with metastatic lung cancer. Multiple whole-chromosome and arm-level gains/losses as well as focal amplifications are present in the pre-
treatment cfDNA sample with high tumor content. A zoomed view of chromosomes 7 and 8 show focal EGFR and FGFR1 amplifications 
in the pre-treatment sample (an activating EGFR L858R mutation was previously detected at 62.5% variant fraction by digital droplet PCR 
[ddPCR]). Low-pass WGS sequencing of a cfDNA sample taken 5 months post-treatment initiation (bottom) showed no detectable copy-
number alterations genome-wide, and no detectable L858R mutation by ddPCR analysis (L858R variant fraction: 0.0%). Low-pass WGS 
copy-number bin size: 500 kbp; segmentation p-value threshold: 0.01.
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TP1337 (see Figure 2A), OCP on cfDNA validated all key 
somatic copy-number alterations detected by low-pass 
cfDNA and detected a 28 bp TP53 frameshift deletion 
(L264del28bp, variant frequency 20.8% with 504 covering 
reads) (Figure 2A). Of note, we observed high correlation 
between gene-level copy number alterations (absolute_
value [targeted NGS log2(CopyNumberRatio)] ≥ 0.5) 
by targeted sequencing and low-pass WGS calls from 
PRINCe assessment of patient cfDNA samples (Pearson 
correlation coefficient: 0.92, p < 0.001), and in silico 
down-sampling experiments in patient and cell line cfDNA 
samples suggest mean coverages as low as 50× enable 
reliable detection of known putative clonal somatic point 
mutations, indels, and copy number variants in samples 
with high tumor content (Supplementary Figures 12 and 
13). Taken together, these results underscore the potential 
for PRINCe followed by targeted sequencing (tuned to 
cfDNA tumor content) as part of a high-throughput, cost-
effective clinical or translational research NGS workflow. 
PRINCe concordance with comprehensive tissue-
based profiling
To assess the potential utility of PRINCe cfDNA 
assessment in the context of comprehensive tissue-based 
precision oncology workflows, we focused on 26 of the 
76 men (34%) with mCRPC profiled by cfDNA low-
pass WGS (corresponding to 31 of 93 (33%) mCRPC 
cfDNA samples) where synchronous or asynchronous 
comprehensive whole exome and whole transcriptome 
profiling was attempted on fresh frozen or FFPE biopsy 
tissue specimens (median number days between tissue- 
and cfDNA specimen collection: 137 (range: 0–682 
days)). Of 26 men, 4 (15%) had either insufficient 
tumor content for comprehensive tissue profiling or 
incomplete tissue profiling data for analysis. Notably, 
all 4 men had cfDNA samples that yielded clinically 
informative results, including 4/4 (100%) with detectable 
focal AR amplification, while 4 of 5 patient-matched 
cfDNA samples were taken pre-biopsy highlighting 
important opportunities for optimized resource allocation 
in precision medicine workflows (see Supplementary 
Results). Collectively, this supports complementary 
clinical utility for plasma cfDNA profiling when paired 
with comprehensive tissue-based NGS workflows as a 
first-stage “screening” strategy.
Global copy number concordance across tissue and 
cfDNA profiling has been poorly explored in mCRPC and 
other cancers. Hence, we next assessed the 22 men with 
comprehensive tissue-based profiling and at least 1 profiled 
cfDNA sample (range of cfDNA samples per individual: 
1–3), of which 18 (82%) had a cfDNA sample w/high 
cfDNA tumor content amenable to analysis (Figure 3A, 
Supplementary Table 2). Despite variable specimen 
tumor content and sample synchronicity, genome-wide 
segmented tissue-based copy-number profiles were 
highly correlated (median r = 0.87 [range: 0.54–0.95]; 
Figure 3B) with whole genome cfDNA segmented copy-
number profiles for the 16 of 18 (89%) individuals with 
fresh frozen tissue specimens, and this concordance was 
not significantly associated with time between cfDNA 
and tissue specimen collection (p = 0.72, two sample 
t-test) (Supplementary Figure 14, Supplementary Table 
3, Supplementary Methods). For 6 of 18 men (33%) with 
high tumor content cfDNA samples and tissue-based 
profiles, clear 21q22.2 copy-number deletions (consistent 
with TMPRSS2:ERG gene fusion) detected by cfDNA 
WGS was also detected in tissue-based DNA profiling, 
with TMPRSS2:ERG fusion isoform expression confirmed 
by tissue-based RNAseq in 5 of 6 men (Supplementary 
Figure 10, Supplementary Table 1). Of 18 men with tissue 
profiling data, 12 (67%) harbored focal AR amplifications 
and 11 of 12 (92%) patient-matched high tumor content 
cfDNA samples show concordant detectable AR 
amplifications (example in Figure 3C; Supplementary 
Table 3). By targeted NGS of patient-matched cfDNA 
samples, 24/28 (86%) somatic point mutations and indels 
present in tissue specimens at variant fractions ≥ 10% 
targeted by our panel were detected in cfDNA samples, 
including 20/21 (95%) in matched high tumor content 
cfDNA samples and 15/15 (100%) in high tumor content 
cfDNA samples collected ≤ 200 days from tissue collection 
(Supplementary Figure 15, Supplementary Tables 4 and 
5). Collectively, these results suggest PRINCe assessment 
of routine cfDNA samples from men in mCRPC may 
enable highly scalable, robust identification of putative 
clonal somatic alterations consistent with comprehensive 
profiling results from synchronous tissue samples.
Clinically relevant discrepancies between 
synchronous cfDNA and tissue profiles, however, were 
also identified. In one patient with a history of both 
primary prostatic adenocarcinoma and a metastatic 
lesion with small cell carcinoma/neuroendocrine 
features (TP1034/MO_1215), PRINCe assessment of 
synchronous (same-day) specimens detected a clear 
focal AR amplification in the cfDNA that was absent in 
the tissue based profiling of a prostatic neuroendocrine/
small cell carcinoma focus (despite identical prioritized 
somatic point mutations), consistent with circulating 
evidence of both AR-driven and AR-independent clones 
(Figure 4A). Further, while previous reports suggest 
cfDNA clonal representation of known early copy-number 
events (including chr8p/8q changes) in men with mCRPC 
may vary over time and therapy [24, 40], analyses in 
our cohort reveal stable representation of early genomic 
events in tissue and serial patient-matched plasma cfDNA 
samples (Figure 4B, Supplementary Results). Overall, 
these results suggest noninvasive profiling may yield high 
concordance with near-synchronous tissue profiling for 
clinically relevant molecular alterations, and may provide 
unique complementary advantages and opportunities for 
expansion into treatment-naïve patient cohorts.
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Evaluating prognostic utility of cfDNA 
biomarkers
cfDNA detectable AR amplification has been reported 
as a biomarker predicting therapeutic resistance to second 
generation anti-androgens (abiraterone/enzalutamide) in 
several studies [23, 52, 53], while circulating tumor cell 
(CTC) detectable ligand independent AR splice variant 
(AR-V7) has been reported as predictive of abiraterone/
enzalutamide resistance and taxane chemotherapy 
sensitivity [63, 64]. While our mCRPC cohort was not 
designed specifically to assess associations between 
circulating biomarkers and clinical outcome or therapeutic 
response, our cohort contained a large number of men 
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on—or starting—second generation anti-androgens, as 
well taxane based chemotherapies. In exploratory analyses 
in our full cohort, we observed an enrichment of cfDNA 
detectable AR amplification in samples from patients 
with limited PSA response (Figure 5A), with both cfDNA 
detectable AR amplification (Kaplan-Meier log-rank test, 
chi-square = 15.3, p < 0.0001; Figure 5B) and elevated 
cfDNA tumor content (Kaplan-Meier log-rank test, chi-
square = 8.2, p < 0.0042; Figure 5C) showing a significant 
association with reduced time on therapy. Further, 
stratifying by therapy (starting or on taxane vs. abiraterone/
enzalutamide), we see that both AR amplification (yes/no) 
(Kaplan-Meier log-rank test, chi-square = 21.9, p<0.0001; 
Figure 5D) or cfDNA tumor content (Kaplan-Meier log-
rank test, chi-square = 18.9, p = 0.0003; Figure 5E) again 
show significant differences in time on therapy, suggesting 
cfDNA detectable AR amplification (and high cfDNA 
tumor content) may be a potentially prognostic marker for 
resistance to both second generation anti-androgen therapy 
and taxane chemotherapies. These results are consistent 
with those seen when restricting analyses to samples from 
patients on or starting therapy separately (Supplementary 
Figure 16), and together confirm previous reports that 
cfDNA detectable AR amplification predicts resistance to 
abiraterone or enzalutamide [23, 52, 53], while supporting 
AR amplification (and high tumor content) as a more 
general poor prognostic factor, similar to circulating tumor 
cell (CTC) count [65, 66].
DISCUSSION
Many comprehensive precision oncology NGS 
approaches carry up-front coverage and sequencing 
requirements (aimed at maximizing sensitivity and 
specificity) that limit clinical implementation across 
cancer types in the current era of limited reimbursement, 
particularly using cfDNA (where estimated tumor content 
can be < 0.01% in early stage disease [27]). Given current 
precision oncology NGS testing is typically performed 
in patients with multiple-therapy refractory advanced 
cancers usually exhibiting significant disease burden 
[67], here we describe a pan-cancer, rapid, inexpensive, 
ultra-low pass NGS cfDNA (PRINCe) based precision 
oncology first stage “screening” approach. Our approach 
can 1) direct therapy in patients with actionable CNAs, 
2) guide precision oncology workflows based on cfDNA 
tumor content approximation in the absence of actionable 
CNAs, and 3) identify genome wide CNA profiles that can 
be used for treatment monitoring. We show this highly 
scalable approach cfDNA WGS approach can be deployed 
at effective whole-genome coverages down to 0.01x from 
as little as 10pg of DNA, and that it facilitates robust 
detection of clinically relevant CNAs and tumor content 
approximation in samples with tumor contents >~10%, 
suggesting substantial utility as a high-throughput, 
cost-effective screening tool in research and clinical 
laboratories (with appropriate validation).
As CNAs may not be informative in all cancers, 
and many patients may have insufficient tumor content to 
identify high level CNAs, results from our approach can be 
used to guide additional precision oncology NGS profiling 
of the same cfDNA sample or fresh frozen or archived 
FFPE tissue-based NGS profiling, with sequencing 
approach and coverage tuned to tumor content. Supporting 
this tiered approach, we performed targeted multiplexed 
PCR based NGS on residual unamplified cfDNA from 
Figure 3: Comparison of synchronous and asynchronous tissue and cfDNA biospecimens collected from patients 
with metastatic castration-resistant prostate cancer (mCRPC) yields highly concordant genome-wide copy number 
profiles. (A) Treatment and cfDNA sample collection timeline plotted in relation to tissue specimen collection date for 26 men with 
metastatic castration-resistant prostate cancer (mCRPC) eligible for tissue-based comprehensive whole-exome and whole-transcriptome 
NGS profiling. Treatment start and cfDNA sample dates are plotted relative to tissue specimen collection date (denoted by solid vertical 
gray line) for each individual. As indicated in the legend, treatments have been divided into 4 separate categories, including: abiraterone 
(orange triangle), enzalutamide (blue hexagon), taxane-based chemotherapy (green ‘X’) and other (yellow circle), and treatment duration is 
indicated by solid black horizontal lines extending rightward from treatment start dates. Therapies categorized as ‘other’ include: radium, 
cisplatin, etoposide, ABT-888, carboplatin, paclitaxel, cabozantinib, olaparib, and UMCC2011.064. Where appropriate, ‘other’ treatment 
including etoposide and cisplatin or carboplatin for individuals with prostate cancer containing small cell/neuroendocrine features are 
noted. As indicated in the legend, samples are colored by LSS-based tumor content approximation with high (LSS > 0.1, red), low (LSS 
< 0.1, blue), and not sequenced (‘N.S.’, brown). For a subset of men, tissue-based molecular data was not available, as indicated by filled 
(tissue data available) or unfilled (tissue data not available) squares. Displayed sample dates are restricted to +/− 800 days from date of 
tissue specimen collection, and therapies administered > 800 days before tissue specimen collection are written at the left-hand side of 
corresponding individual timelines. (B) Correlations between genome-wide tissue and cfDNA segmented copy-number profiles are plotted 
for 16 patients with available comprehensive tissue NGS profiling data and PRINCe assessment of ≥ 1 high tumor content cfDNA sample 
(see Methods). Each point represents the correlation of genome-wide copy number profile for a single cfDNA sample as compared to the 
patient-matched tissue-based copy-number profile. A box-and-whisker plot behind points indicates the interquartile range (IQR), with the 
top and bottom of box representing 25th and 75th percentile, respectively, while bold horizontal line within the box represents the median 
correlation value. Whiskers stretch to 1.5 times the IQR for this sample distribution. (C) Tissue whole exome sequencing (WES) (top; tissue 
id: TP_2093) and cfDNA low-pass whole genome sequencing (WGS) (bottom; cfDNA id: TP1303) genome-wide copy-number profiles for 
biospecimens collected on the same day from a patient with mCRPC (TP_2093). Genome-wide copy-number concordance is statistically 
significant (Pearson correlation coefficient: 0.94, p < 0.001), and focal 2-copy deletion of PTEN and focal high-level AR amplification are 
cleared detected in both the tissue and cfDNA as indicated. A TP53 splice variant (NM_000546:exon 6:c.559+1G>A) identified via WES 
tissue profiling (91.7% variant fraction (VF), 846 covering reads) is also detected by cfDNA targeted NGS (48.5% VF, 853 covering reads). 
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61 cfDNA samples from patients with advanced cancer, 
confirming focal amplifications and identifying potentially 
informative mutations and indels at high concordance with 
known putative clonal alterations (25/26, 96%) in cfDNA 
samples with high tumor content. Comparisons between 
cfDNA and comprehensive tissue-based profiling in a 
subset of patients highlight substantial concordance for 
both somatic mutational and copy-number profiles, while 
elucidating important potentially complementary utility 
for cfDNA-based profiling strategies. 
Limitations of our approach include the need for 
multiple assays, particularly in tumor types with few 
CNAs or where chromosomal rearrangements must be 
assessed. Likewise, in clinical scenarios where cfDNA 
tumor content is expected to be very low, up front 
ultra-deep cfDNA sequencing or ddPCR (as currently 
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performed) is more appropriate, though our ability to 
detect known early broad copy-number events (e.g., 8p 
loss, 8q gain) in prostate carcinoma progression at low 
cfDNA tumor content (see Supplementary Figure 9) 
suggests potential expanded utility of our approach 
at lower tumor contents than currently implemented 
(paired with more comprehensive approaches when 
necessary). Further refinement of our tumor content 
approximation approach (see Supplementary Methods) 
through assessment of informative heterozygous SNPs 
or incorporation of a matched normal genomic DNA 
would enhance the precision and lower limits of our 
tumor-derived cfDNA fraction estimates, though costs 
and feasibility in a clinical sequencing workflow are key 
considerations. While PRINCe is necessarily limited 
to megabase resolution for copy number alteration 
detection at ultra-low-pass (~0.01x) whole-genome 
coverage, smaller (multi-kilobase) clinically relevant focal 
alterations (including focal PTEN deletion) can clearly 
be detected at 0.01–0.1x genome-wide coverages with 
sufficient cfDNA tumor content (Figure 5B). Importantly, 
our approach can be routinely completed in 2–3 days and 
when performed at 50% capacity on an Ion Torrent Proton 
sequencer (currently limited by Ion Torrent barcodes 
incorporated in ThruPLEX library construction), 96 
samples could be sequenced per single Ion Torrent Proton 
P1 chip at list reagent costs of ~$70 per sample for library 
construction and NGS. Taken together, these observations 
suggest the proposed workflow may be amenable to high 
volume, cost-effective ultra-low-pass WGS screening 
protocols. 
Applied to a large mCRPC cohort, our approach 
showed high overall concordance between our cfDNA 
genome-wide CNA profiles with tissue-based profiles 
derived from whole exome sequencing in a precision 
medicine program [45]. In addition, we demonstrated that 
cfDNA detectable AR amplification not only predicts poor 
response to second generation anti-androgens, consistent 
with other published reports [23, 53], but it also portends 
poor prognosis for patients treated with taxane based 
chemotherapy. Hence, cfDNA detectable AR amplification 
may be a more general poor prognostic factor, unlike AR-
v7, which has been reported to confer resistance to anti-
androgens and sensitivity to taxanes [63, 64]. An important 
limitation of these results is that this was not assessed in 
the context of a clinical trial, and men in our study treated 
with taxanes were more advanced and had been treated 
with more lines of therapy post-ADT. Hence, prospective 
confirmation of our findings will be required.
In summary, we have demonstrated the feasibility 
and potential utility of PRINCe, a broadly applicable, rapid, 
inexpensive cfDNA WGS screening assay for precision 
oncology that can robustly detect clinically informative 
CNAs from cfDNA at low tumor content using effective 
whole-genome coverage as low as 0.01×. This screen, 
while most informative in those patients with actionable 
CNAs and tumor content > 10%, can nevertheless be 
used to guide additional testing in all patients based on 
Figure 4: Unique precision oncology considerations identified via serial and synchronous tissue and cfDNA NGS-based 
profiling in patients with advanced prostate cancer. (A) Genome-wide (tissue and cfDNA) and targeted (cfDNA only) NGS 
copy number profiles are displayed, along with treatment and sample timeline, for synchronous (same-day) tissue and cfDNA specimens 
from a patient with metastatic castration-resistant prostate cancer (mCRPC) with a history of both primary prostatic adenocarcinoma and 
a metastatic lesion with small cell carcinoma/neuroendocrine features. Tissue whole exome sequencing (WES) copy number analysis of 
a frozen perirectal mass tissue biopsy specimen (top left) revealed focal, deep deletions in both PTEN and RB1, and no AR copy-number 
alterations, consistent with histological reports of high-grade poorly differentiated carcinoma with neuroendocrine features. Individual 
dots in tissue WES copy-number profile represent exon-level copy-number estimates displayed in genome order, and dots are colored by 
corresponding chromosomes. cfDNA low-pass whole genome sequencing (WGS) copy number profiling identified focal deep deletions 
in PTEN and RB1, as well as high level focal AR amplification, highlighting circulating evidence of both AR-driven and AR-independent 
clones. Individual dots in cfDNA low-pass WGS plot represent bin-level copy-number estimates displayed in genome order (left to right), 
with segmented copy-number alterations represented by orange horizontal lines. Both tissue (WES) and cfDNA (targeted NGS; copy-
number prfile ) mutation profiling identified a TSC1 germline H732Y pathogenic variant (tissue: 48% variant fraction (VF), 79 covering 
reads; cfDNA: 60% VF, 160 covering reads) and somatic TP53 frameshift deletion (p.R333fs; tissue: 49% VF, 189 covering reads; cfDNA: 
17%, 1865 covering reads), while cfDNA targeted NGS identified a BRCA2 frameshift insertion (p.S2186fs; 18% VF, 396 covering reads) 
not present in the tissue sample, further supporting detection of multiple clones via cfDNA PRINCe assessment. The cfDNA targeted 
NGS copy number profile is presented at right, showing confirmation of focal PTEN and RB1 deletions along with high-level focal AR 
amplification as seen by low-pass WGS. Zoomed view of treatment and sample timeline for this patient is presented at bottom, as previously 
described (see Figure 3). (B) Genome-wide (left) and chromosome 8 (right) copy number profiles from multiple biospecimens taken over 
time from a single patient with metastatic castration-resistant prosate cancer (mCRPC) (tissue id: MO_1041; cfDNA ids: TP1105 and 
TP1151). WES of a formalin fixed paraffin embedded (FFPE) tissue biopsy specimen (top left) revealed low but detectable tumor content, 
and identified copy-number loss affecting 8p and arm-level gain of 8q (at right). Low-pass WGS of a cfDNA specimen collected almost 
2 years after tissue biopsy (TP1105, middle left) revealed elevated cfDNA tumor content with frequent copy-number alterations genome-
wide, including copy-number loss affecting chr8p and arm-level gain of chr8q (displayed at right), as detected in initial tissue profiling. A 
subsequent cfDNA sample (TP1151) again showed detection of elevated cfDNA tumor content and a highly concordant genome-wide copy 
number profile, with faithful representation of the 8p loss and 8q gain events detected in previous specimens. Overall, these results highlight 
the consistent representation of early genomic events as inferred from circulating tumor DNA profiled in our cohort.
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cfDNA tumor content approximation. Our approach 
highlights important potential clinical utility when paired 
with targeted cfDNA NGS and/or tissue-based workflows, 
and demonstrates unique possibilities for inexpensive 
disease monitoring. More generally, our study supports the 
potential utility of tiered approaches in precision oncology, 
rather than using costlier front-line approaches defined by 
performance necessary in the extremes. 
MATERIALS AND METHODS
TCGA data analysis
TCGA pan-cancer copy number analyses were run 
on somatic segmented Affymetrix SNP6 array-based copy-
number calls for 11,576 tumor samples across 32 tumor 
types contained in the January 28, 2016 TCGA GDAC 
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Firehose standard data run (stddata__2016_01_28) [68] 
(see Supplementary Methods). 
Cell-free DNA extraction 
Five milliliters of peripheral blood were collected 
for 93 samples from 76 patients with mCRPC and 10 
healthy controls (5 male, 5 female) using K2 EDTA blood 
collection tubes (Cat: 366643, BD, NJ) (Supplementary 
Table 1), and cfDNA was isolated as described (see 
Supplementary Methods). For 31 samples from 24 patients 
with other advanced cancers (Supplementary Table 1), 10 
mL peripheral blood was collected using Streck Cell-Free 
DNA BCT tube (Streck; NE) and cfDNA was isolated as 
detailed (see Supplementary Methods). 
VCaP and UMUC-5 In vitro dilution
We carried out in vitro dilution experiments using 
serially diluted genomic DNA from 1) VCaP cells 
(metastatic prostate cancer cell line) with normal male 
human cell-free genomic DNA at 50%, 25%, 10%, 5%, 
1% and 0% dilutions, and 2) UMUC-5 cells (urothelial 
cancer cell line) with normal male human cell-free 
genomic DNA at 50%, 10%, 5%, 0% dilutions. Cell line 
DNA was fragmented to approximately 180 bp by Covaris 
AFA (Woburn, MA) focused ultrasonication. Library 
preparation and sequencing from undiluted and serial 
dilution samples was performed as for patient samples 
described below. 
ThruPLEX library preparation
Whole genome amplified (WGA) libraries were 
prepared from either cell-free DNA (cfDNA) isolated from 
plasma samples (median of 2.9 ng cfDNA, interquartile 
range [IQR] 1.73–5.79 ng, see Supplementary Table 1) or 
Covaris-sheared and size selected (~ 180 bp size) VCaP 
(1.9 ng) or UMUC-5 (2.0 ng) genomic DNA (gDNA) using 
the ThruPLEX RGP-0003 prototype (Takara Bio USA; 
Ann Arbor, MI) according to the manufacturer’s protocol. 
Libraries were quantified using Ion Library Quantification 
kit by qPCR, and sequenced with 2–16 samples per Proton 
PI chip on an Ion Proton sequencer (Ion Torrent, Carlsbad, 
CA) according to the manufacturer’s instructions.
Low-pass WGS and copy-number detection
Sequencing alignment and coverage analyses were 
performed using Torrent Suite version 5.0.2 (Ion Torrent, 
Carlsbad, CA). Genome-wide copy number alterations 
were first called from aligned, non-PCR-duplicate reads 
using the QDNASeq R package (version 1.6.1) [69]. 
Segmented copy-number events were identified using 
bin-level corrected, median- and control-normalized read 
counts using the circular binary segmentation algorithm 
implemented by the DNACopy (1.44.0) R package, and 
final segment- and bin-level copy-number values were used 
for subsequent analyses as described (see Supplementary 
Methods). Focal CNAs were defined as CNAs 1.5–20 Mb 
long with a log2(CopyNumberRatio) ≥ 0.2.
Targeted sequencing: oncomine comprehensive 
assay (OCP)
For 61 patient cfDNA samples (see Supplementary 
Table 1) and both sheared UMUC-5 and VCaP gDNA 
samples, we performed targeted NGS using the DNA 
component of the OCP, a custom multiplexed PCR-
based panel of 2,530 amplicons targeting 126 genes [4]. 
Library preparation, data analysis, and variant and copy-
number annotation and prioritization was carried out 
essentially as described for each sample [4, 70–72] using 
validated in house pipelines (Supplementary Table 1; see 
Supplementary Methods). 
In silico experiments and tumor content 
approximation
To establish theoretical segment-level copy-
number distributions for tumor content approximation 
and examine efficacy across variable effect whole-
Figure 5: Exploratory analyses of association between circulating biomarkers and outcome in patients with metastatic 
castration-resistant prostate cancer (mCRPC) supports cfDNA detectable AR amplification as a poor overall prognostic 
factor independent of treatment type. (A) Waterfall plot summarizing prostate specific antibody (PSA) response for all samples 
from men with mCRPC with complete PSA data (n = 90). Height of bars represent the percentage change in PSA response as calculated 
by subtracting the PSA level at sample date from the best PSA observed after sample date while on the current or initiated treatment, and 
dividing by starting PSA value. Bars are ordered horizontally within treatment category (Abi/Enza, Taxane, or Other) by PSA response. Bars 
are colored by cfDNA detectable AR amplification status (yellow = cfDNA detectable AR amplification; gray = no cfDNA detectable AR 
amplification) and bars corresponding to samples taken from men who have received more than one line of therapy post-ADT are outlined 
in bold. (B–E) Kaplan-Meier survival curves are plotted for analyses exploring association between cfDNA detectable AR amplification (B, 
D) or cfDNA tumor content (C, E) and total time on therapy in both unstratified (B-C) and stratified (D-E; by treatment type) analyses of our 
mCRPC cohort. Unstratified analysis of single cfDNA samples from men on or starting taxane-based chemotherapy or second-generation 
anti-androgens abiraterone or enzalutamide (n = 57 men) highlight significant differences in time on therapy for both (B) cfDNA detectable 
AR amplification (Kaplan-Meier log-rank test, chi-square = 15.3, p < 0.0001) and (C) elevated cfDNA tumor content (Kaplan-Meier log-
rank test, chi-square = 8.2, p < 0.0042). Analyses stratified by treatment (starting or on taxane vs. abiraterone/enzalutamide) show (D) 
cfDNA detectable AR amplification (yes/no) (Kaplan-Meier log-rank test, chi-square = 21.9, p < 0.0001) and (E) cfDNA tumor content 
(Kaplan-Meier log-rank test, chi-square = 18.9, p = 0.0003) again demonstrate significant differences in time on therapy. Survival curves 
are colored by corresponding strata, and risk tables at selected timepoints are displayed below each Kaplan-Meier plot. 
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genome coverages (0.005–0.01x), we carried out serial 
in silico dilution and downsampling experiments on 
artificial cfDNA VCaP and UMUC-5 WGS data and 
patient cfDNA samples (see Supplementary Methods). 
Using computational experiments on in vitro and in silico 
VCaP and UMUC-5 cell line dilution data as described in 
Supplementary Methods, a heuristic least squares based 
distance metric (LSS) was used to approximate tumor 
content from whole-genome copy-number data, and 
guide tumor content approximation for patient samples, 
with low tumor content samples (LSS < 0.1) specifically 
scanned for focal CNAs as described (see Supplementary 
Methods).
Cell line cfDNA WGS vs COSMIC array-based 
CN calls 
To evaluate the capacity of low-pass cfDNA WGS 
to detect copy-number alterations across variable tumor 
content, segmented cfDNA WGS copy-number calls for 
VCaP and UMUC-5 in vitro dilutions were compared 
to publically available COSMIC and targeted NGS 
copy-number calls, respectively (see Supplementary 
Methods). 
Concordance with tissue-based whole-exome 
sequencing copy-number profiles 
Segmented log2 copy number ratio and point 
mutation data from whole-exome sequencing of fresh 
frozen tissue specimens [10, 45] was available for 22 of 
26 patients also profiled by cfDNA low-pass WGS and 
compared to patient-matched cfDNA WGS profiles (see 
Supplementary Methods). 
Clinical information 
All clinical and outcome information was collected, 
retrieved, and analyzed from internal patient tracking 
databases and University of Michigan Health System 
(UMHS) electronic health records by IRB-approved 
personnel. 
Statistical analyses
All statistical analyses described were carried out 
in R (3.2.3).
Abbreviations
cfDNA – Cell-free DNA; CNA – Copy-number 
alterations; CRPC – Castration-resistant prostate cancer; 
ddPCR – Digital droplet polymerase chain reaction; NGS 
– Next-generation sequencing; OCP – Oncomine Cancer 
Assay; SNV – Single nucleotide variant; WGS – Whole 
genome sequencing.
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